Keiran S M Smalley

发表

Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion.

Eric Brown, Meenhard Herlyn, M. Herlyn, 2005, The American journal of pathology.

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.

K. Smalley, R. Kudchadkar, K. Paraiso, 2012, Cancer journal.

Selective evolutionary pressure from the tissue microenvironment drives tumor progression.

Meenhard Herlyn, M. Herlyn, K. Smalley, 2005, Seminars in cancer biology.

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

K. Smalley, Keiran S M Smalley, Manali S Phadke, 2015, Molecular Cancer Therapeutics.

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

Keith T Flaherty, Meenhard Herlyn, K. Flaherty, 2006, Molecular Cancer Therapeutics.

The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.

K. Smalley, Keiran S M Smalley, Michael F Emmons, 2016, Biochemical pharmacology.

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.

Yian A Chen, Dirk Schadendorf, John M Koomen, 2019, Cancer research.

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

Hieu T. Do, Meenhard Herlyn, David M. Wilson, 2006, Cancer research.

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.

Chelsea C Pinnix, Min Xiao, Meenhard Herlyn, 2006, Cancer research.

Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.

Alexander R A Anderson, K. Smalley, Eunjung Kim, 2016, European journal of cancer.